Furthermore, the downregulation of this miRNA promotes tumorigenesis (Wang et al., 2020a) in colorectal cancer through IGFBP2 and ITGA3 genes, and in bladder cancer, it is associated with accelerated tumor progression (Jiang P. et al., 2020; Yang et al., 2020), hsa-miR-1184 has been proposed as a potential serum biomarker to distinguish between benign prostatic hyperplasia (BPH) and prostate cancer (Knyazev et al., 2016). Here, IGFBP2 is linked to urinary bladder cancer.